Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Lymphocytic, Chronic, B-Cell | 231 | 2024 | 1628 | 26.950 |
Why?
|
Lymphocytosis | 24 | 2023 | 119 | 8.180 |
Why?
|
Receptors, Antigen, B-Cell | 37 | 2023 | 545 | 4.380 |
Why?
|
B-Lymphocytes | 59 | 2023 | 4742 | 4.280 |
Why?
|
Pyrazoles | 27 | 2024 | 1999 | 3.400 |
Why?
|
Pyrimidines | 29 | 2024 | 3016 | 3.110 |
Why?
|
Adenine | 35 | 2024 | 975 | 2.980 |
Why?
|
Piperidines | 42 | 2024 | 1650 | 2.470 |
Why?
|
Genes, Immunoglobulin | 13 | 2024 | 285 | 2.140 |
Why?
|
Immunoglobulin Heavy Chains | 30 | 2024 | 649 | 1.910 |
Why?
|
Pyrazines | 15 | 2024 | 1199 | 1.890 |
Why?
|
Benzamides | 14 | 2024 | 1369 | 1.760 |
Why?
|
Immunoglobulin Variable Region | 24 | 2024 | 419 | 1.540 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 10 | 2022 | 179 | 1.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2024 | 11712 | 1.280 |
Why?
|
Toll-Like Receptors | 11 | 2023 | 590 | 1.240 |
Why?
|
Protein Kinase Inhibitors | 22 | 2024 | 5643 | 1.220 |
Why?
|
Complementarity Determining Regions | 10 | 2020 | 149 | 1.170 |
Why?
|
Neoplasm, Residual | 9 | 2022 | 1007 | 1.110 |
Why?
|
Lymphoma, Follicular | 7 | 2022 | 453 | 1.110 |
Why?
|
Antineoplastic Agents | 33 | 2024 | 13630 | 1.100 |
Why?
|
Hematologic Neoplasms | 8 | 2023 | 1895 | 1.090 |
Why?
|
Quinazolinones | 11 | 2022 | 223 | 1.050 |
Why?
|
Lymphoma, Mantle-Cell | 8 | 2022 | 237 | 1.030 |
Why?
|
Lymphocyte Count | 14 | 2021 | 780 | 1.030 |
Why?
|
Gene Expression Regulation, Leukemic | 17 | 2021 | 646 | 1.020 |
Why?
|
Tumor Suppressor Protein p53 | 14 | 2024 | 2919 | 1.020 |
Why?
|
I-kappa B Proteins | 2 | 2024 | 212 | 1.010 |
Why?
|
Lymphoma, B-Cell | 11 | 2022 | 935 | 1.000 |
Why?
|
Precancerous Conditions | 5 | 2023 | 977 | 0.990 |
Why?
|
Purines | 13 | 2022 | 605 | 0.970 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2016 | 693 | 0.970 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 10 | 2015 | 91 | 0.940 |
Why?
|
Lymphoma | 6 | 2023 | 1898 | 0.910 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 16 | 2021 | 101 | 0.900 |
Why?
|
Chromosomes, Human, Pair 17 | 4 | 2020 | 419 | 0.890 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 179 | 0.880 |
Why?
|
Antigens, Neoplasm | 6 | 2020 | 1998 | 0.860 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 4 | 2021 | 57 | 0.820 |
Why?
|
Splenic Neoplasms | 6 | 2022 | 95 | 0.820 |
Why?
|
Immunogenetics | 7 | 2018 | 66 | 0.810 |
Why?
|
Humans | 277 | 2024 | 760621 | 0.800 |
Why?
|
Chlorambucil | 6 | 2022 | 42 | 0.790 |
Why?
|
Leukemia, B-Cell | 4 | 2016 | 84 | 0.780 |
Why?
|
Chromosome Deletion | 6 | 2020 | 1387 | 0.780 |
Why?
|
Immunophenotyping | 18 | 2022 | 1871 | 0.740 |
Why?
|
Immunoglobulins | 9 | 2022 | 859 | 0.720 |
Why?
|
Mutation | 39 | 2024 | 29932 | 0.720 |
Why?
|
Vidarabine | 7 | 2020 | 336 | 0.710 |
Why?
|
NF-kappa B | 5 | 2024 | 2488 | 0.680 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2020 | 824 | 0.670 |
Why?
|
Prognosis | 38 | 2022 | 29658 | 0.590 |
Why?
|
Sequence Analysis, Protein | 1 | 2018 | 258 | 0.580 |
Why?
|
Chemokines, CC | 4 | 2003 | 283 | 0.560 |
Why?
|
Chromosome Aberrations | 8 | 2022 | 1764 | 0.560 |
Why?
|
Pyridinium Compounds | 1 | 2017 | 81 | 0.560 |
Why?
|
Aged, 80 and over | 50 | 2024 | 58995 | 0.550 |
Why?
|
Aged | 86 | 2024 | 169152 | 0.520 |
Why?
|
Hedgehogs | 1 | 2015 | 5 | 0.520 |
Why?
|
Clonal Anergy | 3 | 2016 | 171 | 0.520 |
Why?
|
High-Throughput Nucleotide Sequencing | 12 | 2024 | 3616 | 0.510 |
Why?
|
Tumor Microenvironment | 17 | 2024 | 3844 | 0.480 |
Why?
|
Apoptosis | 16 | 2024 | 9501 | 0.470 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 280 | 0.450 |
Why?
|
Hematology | 2 | 2020 | 241 | 0.450 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2022 | 9276 | 0.440 |
Why?
|
Antibodies, Monoclonal | 7 | 2018 | 9185 | 0.430 |
Why?
|
Drug Resistance, Neoplasm | 12 | 2023 | 5253 | 0.430 |
Why?
|
Cancer Vaccines | 1 | 2020 | 1046 | 0.420 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2019 | 8515 | 0.420 |
Why?
|
Multiple Myeloma | 5 | 2023 | 5130 | 0.420 |
Why?
|
Lipoproteins, HDL | 1 | 2017 | 667 | 0.410 |
Why?
|
Lectins | 1 | 2014 | 484 | 0.400 |
Why?
|
Male | 100 | 2024 | 359744 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2016 | 1407 | 0.390 |
Why?
|
Flow Cytometry | 12 | 2019 | 5870 | 0.390 |
Why?
|
Clone Cells | 9 | 2013 | 1660 | 0.390 |
Why?
|
Sulfonamides | 7 | 2023 | 1977 | 0.380 |
Why?
|
T-Lymphocytes | 14 | 2023 | 10181 | 0.380 |
Why?
|
Female | 99 | 2024 | 391270 | 0.380 |
Why?
|
Tumor Lysis Syndrome | 2 | 2022 | 38 | 0.370 |
Why?
|
Middle Aged | 75 | 2024 | 220352 | 0.370 |
Why?
|
Quality of Life | 3 | 2023 | 13308 | 0.370 |
Why?
|
Immunotherapy | 6 | 2019 | 4642 | 0.360 |
Why?
|
Leukemia | 1 | 2018 | 1520 | 0.350 |
Why?
|
Bone Marrow | 10 | 2022 | 2912 | 0.350 |
Why?
|
Blood Proteins | 6 | 2016 | 1173 | 0.340 |
Why?
|
Molecular Targeted Therapy | 8 | 2019 | 2803 | 0.330 |
Why?
|
Recurrence | 11 | 2024 | 8482 | 0.320 |
Why?
|
Stromal Cells | 7 | 2022 | 1326 | 0.320 |
Why?
|
Cyclophosphamide | 5 | 2020 | 2221 | 0.310 |
Why?
|
Leukocytosis | 1 | 2010 | 251 | 0.310 |
Why?
|
Signal Transduction | 25 | 2023 | 23376 | 0.310 |
Why?
|
Disease-Free Survival | 12 | 2020 | 6828 | 0.310 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2013 | 1135 | 0.300 |
Why?
|
Cell Lineage | 2 | 2014 | 2533 | 0.300 |
Why?
|
Cell Movement | 10 | 2024 | 5206 | 0.290 |
Why?
|
MicroRNAs | 6 | 2024 | 3790 | 0.290 |
Why?
|
Animals | 47 | 2024 | 167963 | 0.290 |
Why?
|
Genomics | 5 | 2022 | 5794 | 0.290 |
Why?
|
Survival Analysis | 12 | 2021 | 10182 | 0.290 |
Why?
|
DNA Mutational Analysis | 10 | 2024 | 4107 | 0.280 |
Why?
|
Proto-Oncogene Proteins | 6 | 2024 | 4490 | 0.280 |
Why?
|
Disease Progression | 19 | 2024 | 13502 | 0.280 |
Why?
|
Mice, Transgenic | 14 | 2024 | 9530 | 0.280 |
Why?
|
Mice | 32 | 2024 | 81208 | 0.280 |
Why?
|
Immunoglobulin M | 5 | 2022 | 1529 | 0.260 |
Why?
|
Congresses as Topic | 2 | 2023 | 805 | 0.260 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 6 | 2019 | 112 | 0.260 |
Why?
|
Neoplasm Staging | 8 | 2020 | 11152 | 0.260 |
Why?
|
Burkitt Lymphoma | 4 | 2001 | 333 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3085 | 0.260 |
Why?
|
Neoplasm Proteins | 6 | 2015 | 3610 | 0.260 |
Why?
|
Receptors, Chemokine | 3 | 2003 | 655 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3205 | 0.250 |
Why?
|
Immunoglobulin lambda-Chains | 2 | 2020 | 82 | 0.250 |
Why?
|
Chemotaxis, Leukocyte | 4 | 2016 | 663 | 0.250 |
Why?
|
MAP Kinase Signaling System | 4 | 2022 | 1484 | 0.250 |
Why?
|
Treatment Outcome | 24 | 2024 | 65017 | 0.250 |
Why?
|
Immunoglobulin Light Chains | 5 | 2017 | 286 | 0.240 |
Why?
|
Italy | 5 | 2024 | 841 | 0.240 |
Why?
|
Toll-Like Receptor 9 | 2 | 2017 | 234 | 0.240 |
Why?
|
Adult | 47 | 2024 | 219994 | 0.230 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 621 | 0.230 |
Why?
|
Lymphocyte Activation | 13 | 2021 | 5496 | 0.230 |
Why?
|
ADP-ribosyl Cyclase | 2 | 2005 | 38 | 0.230 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2021 | 4353 | 0.230 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2020 | 1375 | 0.230 |
Why?
|
Spliceosomes | 1 | 2024 | 129 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2020 | 618 | 0.230 |
Why?
|
Mutagenesis, Insertional | 1 | 2006 | 652 | 0.220 |
Why?
|
Gene Deletion | 3 | 2015 | 2668 | 0.220 |
Why?
|
Survival Rate | 11 | 2021 | 12808 | 0.220 |
Why?
|
Receptors, Interleukin-1 | 2 | 2017 | 261 | 0.220 |
Why?
|
Autoantigens | 3 | 2017 | 877 | 0.220 |
Why?
|
Disease Models, Animal | 8 | 2022 | 18137 | 0.220 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 1403 | 0.210 |
Why?
|
Receptor Cross-Talk | 1 | 2003 | 116 | 0.210 |
Why?
|
Sequoia | 1 | 2022 | 6 | 0.210 |
Why?
|
Tumor Cells, Cultured | 11 | 2021 | 6131 | 0.210 |
Why?
|
Kv1.3 Potassium Channel | 1 | 2022 | 7 | 0.210 |
Why?
|
Chemokines | 3 | 2021 | 962 | 0.200 |
Why?
|
Genes, bcl-2 | 2 | 2003 | 119 | 0.200 |
Why?
|
Myeloid Differentiation Factor 88 | 5 | 2022 | 581 | 0.200 |
Why?
|
Tumor Suppressor Proteins | 4 | 2024 | 2802 | 0.200 |
Why?
|
Clinical Trials as Topic | 5 | 2024 | 8056 | 0.200 |
Why?
|
CD40 Ligand | 6 | 2021 | 521 | 0.200 |
Why?
|
Dromaiidae | 1 | 2021 | 7 | 0.200 |
Why?
|
Drug Synergism | 3 | 2020 | 1754 | 0.200 |
Why?
|
Chemokines, CXC | 2 | 2003 | 421 | 0.200 |
Why?
|
Phosphoproteins | 3 | 2024 | 2440 | 0.200 |
Why?
|
Immunotherapy, Adoptive | 4 | 2022 | 1454 | 0.200 |
Why?
|
Follow-Up Studies | 14 | 2022 | 39261 | 0.200 |
Why?
|
Antigens, CD20 | 1 | 2022 | 201 | 0.190 |
Why?
|
Genetic Predisposition to Disease | 7 | 2020 | 17790 | 0.190 |
Why?
|
Disease Susceptibility | 2 | 2018 | 1791 | 0.190 |
Why?
|
Hepatitis C, Chronic | 1 | 2010 | 1031 | 0.190 |
Why?
|
Amino Acid Sequence | 13 | 2018 | 13451 | 0.190 |
Why?
|
Genes, T-Cell Receptor | 1 | 2020 | 30 | 0.190 |
Why?
|
Hemorrhage | 7 | 2023 | 3600 | 0.190 |
Why?
|
Cell Proliferation | 6 | 2024 | 10446 | 0.180 |
Why?
|
RNA, Messenger | 7 | 2022 | 12766 | 0.180 |
Why?
|
Cell Communication | 4 | 2016 | 1653 | 0.180 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2020 | 23 | 0.180 |
Why?
|
Isoquinolines | 2 | 2020 | 353 | 0.180 |
Why?
|
Tosyl Compounds | 1 | 2020 | 112 | 0.180 |
Why?
|
Immunological Synapses | 1 | 2020 | 59 | 0.180 |
Why?
|
Vaccines, Subunit | 1 | 2020 | 161 | 0.180 |
Why?
|
Extracellular Space | 1 | 2002 | 564 | 0.170 |
Why?
|
Leukemia, Myeloid | 1 | 2003 | 695 | 0.170 |
Why?
|
Atrial Fibrillation | 5 | 2023 | 5209 | 0.170 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 3 | 2015 | 69 | 0.170 |
Why?
|
Tretinoin | 2 | 2018 | 519 | 0.170 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2024 | 633 | 0.170 |
Why?
|
DNA Methylation | 4 | 2019 | 4373 | 0.170 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2020 | 76 | 0.170 |
Why?
|
Spleen | 5 | 2022 | 2298 | 0.170 |
Why?
|
Immunoglobulin D | 2 | 2016 | 57 | 0.170 |
Why?
|
T-Lymphocyte Subsets | 1 | 2007 | 1810 | 0.170 |
Why?
|
Phenotype | 11 | 2022 | 16546 | 0.170 |
Why?
|
Diagnosis, Differential | 7 | 2018 | 12965 | 0.170 |
Why?
|
Liver Cirrhosis | 1 | 2010 | 1931 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2020 | 3584 | 0.160 |
Why?
|
Aspergillus fumigatus | 1 | 2020 | 156 | 0.160 |
Why?
|
Ecosystem | 1 | 2023 | 485 | 0.160 |
Why?
|
Autoimmunity | 1 | 2007 | 1370 | 0.160 |
Why?
|
Taiwan | 2 | 2017 | 505 | 0.160 |
Why?
|
Salvage Therapy | 4 | 2020 | 1268 | 0.160 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 76 | 0.160 |
Why?
|
Hereditary Angioedema Types I and II | 1 | 2018 | 10 | 0.160 |
Why?
|
Antigens, CD | 6 | 2012 | 4000 | 0.160 |
Why?
|
Cell Survival | 10 | 2021 | 5797 | 0.160 |
Why?
|
Immunoglobulin Isotypes | 1 | 2018 | 158 | 0.160 |
Why?
|
DNA-Binding Proteins | 6 | 2015 | 9585 | 0.160 |
Why?
|
Aspergillosis | 1 | 2020 | 243 | 0.160 |
Why?
|
Immunoglobulin Class Switching | 2 | 2019 | 289 | 0.160 |
Why?
|
Cytogenetic Analysis | 2 | 2016 | 271 | 0.160 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1056 | 0.160 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 3 | 2015 | 801 | 0.160 |
Why?
|
Cytogenetics | 1 | 2019 | 198 | 0.160 |
Why?
|
Leukocytes, Mononuclear | 4 | 2024 | 1827 | 0.150 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2005 | 1765 | 0.150 |
Why?
|
Choice Behavior | 1 | 2024 | 821 | 0.150 |
Why?
|
Retrospective Studies | 13 | 2023 | 80372 | 0.150 |
Why?
|
Epigenomics | 2 | 2021 | 936 | 0.150 |
Why?
|
Cell Line, Tumor | 13 | 2022 | 16939 | 0.150 |
Why?
|
Disease Management | 4 | 2018 | 2514 | 0.150 |
Why?
|
Bone Marrow Cells | 4 | 2012 | 2414 | 0.150 |
Why?
|
Hepatitis B, Chronic | 1 | 2022 | 403 | 0.150 |
Why?
|
Antigens | 3 | 2023 | 1447 | 0.150 |
Why?
|
Gene Rearrangement | 5 | 2021 | 1122 | 0.150 |
Why?
|
Neoplasm Transplantation | 4 | 2020 | 2014 | 0.150 |
Why?
|
Translocation, Genetic | 4 | 2016 | 1388 | 0.150 |
Why?
|
Anilides | 1 | 2020 | 409 | 0.150 |
Why?
|
Cells, Cultured | 11 | 2017 | 18957 | 0.140 |
Why?
|
Indolizines | 1 | 2017 | 30 | 0.140 |
Why?
|
Chemokine CCL22 | 3 | 2002 | 27 | 0.140 |
Why?
|
Cyclic N-Oxides | 1 | 2017 | 73 | 0.140 |
Why?
|
Macrophages | 3 | 2020 | 5745 | 0.140 |
Why?
|
Cell Culture Techniques | 2 | 2022 | 1664 | 0.140 |
Why?
|
Coculture Techniques | 6 | 2021 | 1342 | 0.140 |
Why?
|
Preleukemia | 3 | 2010 | 34 | 0.140 |
Why?
|
Aging | 2 | 2007 | 8651 | 0.140 |
Why?
|
Receptor, IGF Type 1 | 1 | 2019 | 380 | 0.140 |
Why?
|
Chromogranin A | 1 | 2016 | 49 | 0.140 |
Why?
|
Immunologic Surveillance | 1 | 2017 | 92 | 0.140 |
Why?
|
Camptothecin | 1 | 2020 | 590 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2007 | 4550 | 0.130 |
Why?
|
Calreticulin | 1 | 2017 | 115 | 0.130 |
Why?
|
Receptors, Notch | 1 | 2021 | 743 | 0.130 |
Why?
|
Cysteine | 1 | 2021 | 895 | 0.130 |
Why?
|
Cytidine Deaminase | 2 | 2015 | 245 | 0.130 |
Why?
|
Consensus | 3 | 2022 | 3113 | 0.130 |
Why?
|
Base Sequence | 4 | 2018 | 12446 | 0.130 |
Why?
|
Adoptive Transfer | 1 | 2018 | 822 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2024 | 10344 | 0.130 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 114 | 0.130 |
Why?
|
Binding, Competitive | 1 | 2017 | 1142 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 995 | 0.130 |
Why?
|
Nitriles | 1 | 2020 | 956 | 0.130 |
Why?
|
Gene Expression Profiling | 9 | 2019 | 9411 | 0.120 |
Why?
|
Azacitidine | 1 | 2017 | 334 | 0.120 |
Why?
|
Hypertension | 4 | 2023 | 8594 | 0.120 |
Why?
|
Chromosomes, Human, Pair 13 | 2 | 2014 | 193 | 0.120 |
Why?
|
Adaptor Proteins, Signal Transducing | 7 | 2017 | 2895 | 0.120 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2014 | 44 | 0.120 |
Why?
|
Mice, Inbred BALB C | 3 | 2014 | 6216 | 0.120 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.120 |
Why?
|
Gene Frequency | 6 | 2021 | 3615 | 0.120 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2014 | 283 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1189 | 0.120 |
Why?
|
Multigene Family | 3 | 2024 | 1077 | 0.120 |
Why?
|
Receptors, Antigen | 1 | 2014 | 51 | 0.120 |
Why?
|
DNA, Antisense | 1 | 2013 | 44 | 0.110 |
Why?
|
Blotting, Western | 3 | 2017 | 5039 | 0.110 |
Why?
|
Toll-Like Receptor 2 | 1 | 2016 | 348 | 0.110 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 311 | 0.110 |
Why?
|
I-kappa B Kinase | 1 | 2015 | 251 | 0.110 |
Why?
|
Thionucleotides | 1 | 2013 | 112 | 0.110 |
Why?
|
Diarrhea | 5 | 2019 | 1319 | 0.110 |
Why?
|
Monocytes | 1 | 2003 | 2575 | 0.110 |
Why?
|
Sweden | 1 | 2016 | 1381 | 0.110 |
Why?
|
Ribosomal Proteins | 1 | 2015 | 363 | 0.110 |
Why?
|
Age Factors | 3 | 2020 | 18416 | 0.110 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2005 | 0.110 |
Why?
|
Mice, Knockout | 6 | 2016 | 14372 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 640 | 0.110 |
Why?
|
Remission Induction | 3 | 2015 | 2392 | 0.110 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15840 | 0.110 |
Why?
|
Membrane Glycoproteins | 6 | 2012 | 3707 | 0.110 |
Why?
|
Molecular Sequence Data | 8 | 2014 | 17624 | 0.100 |
Why?
|
Polymerase Chain Reaction | 4 | 2012 | 6068 | 0.100 |
Why?
|
Toll-Like Receptor 7 | 1 | 2014 | 177 | 0.100 |
Why?
|
Gene Expression | 7 | 2021 | 7588 | 0.100 |
Why?
|
Cladribine | 1 | 2012 | 34 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2016 | 2418 | 0.100 |
Why?
|
Alleles | 4 | 2016 | 6898 | 0.100 |
Why?
|
Models, Biological | 6 | 2015 | 9467 | 0.100 |
Why?
|
Biomimetics | 1 | 2013 | 173 | 0.100 |
Why?
|
Epigenesis, Genetic | 3 | 2021 | 3758 | 0.100 |
Why?
|
Chemokine CCL17 | 2 | 2002 | 26 | 0.100 |
Why?
|
Thalidomide | 1 | 2017 | 884 | 0.100 |
Why?
|
Cytoskeleton | 3 | 2014 | 1167 | 0.100 |
Why?
|
Cohort Studies | 11 | 2021 | 41335 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2014 | 368 | 0.100 |
Why?
|
Iron | 1 | 2020 | 1786 | 0.100 |
Why?
|
Gene Targeting | 1 | 2015 | 839 | 0.100 |
Why?
|
Nuclear Proteins | 3 | 2017 | 5791 | 0.100 |
Why?
|
Flavonoids | 1 | 2015 | 445 | 0.100 |
Why?
|
Blood Donors | 1 | 2013 | 343 | 0.100 |
Why?
|
Genes, p53 | 1 | 2014 | 713 | 0.100 |
Why?
|
Receptors, IgE | 2 | 2011 | 372 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7475 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1442 | 0.100 |
Why?
|
Protein Binding | 3 | 2017 | 9335 | 0.090 |
Why?
|
bcl-2-Associated X Protein | 2 | 2005 | 282 | 0.090 |
Why?
|
Risk Factors | 7 | 2022 | 74359 | 0.090 |
Why?
|
Down-Regulation | 2 | 2019 | 2913 | 0.090 |
Why?
|
Lymphocytes | 2 | 2012 | 2611 | 0.090 |
Why?
|
Chemokine CXCL13 | 2 | 2018 | 59 | 0.090 |
Why?
|
Hedgehog Proteins | 1 | 2015 | 769 | 0.090 |
Why?
|
Lymphoproliferative Disorders | 1 | 2014 | 533 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3143 | 0.090 |
Why?
|
Genetic Association Studies | 2 | 2017 | 2717 | 0.090 |
Why?
|
Neutropenia | 3 | 2023 | 884 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8624 | 0.090 |
Why?
|
src-Family Kinases | 1 | 2013 | 535 | 0.090 |
Why?
|
Mortality | 1 | 2021 | 2916 | 0.090 |
Why?
|
Ribonucleases | 1 | 2010 | 277 | 0.090 |
Why?
|
Cell Differentiation | 5 | 2012 | 11481 | 0.090 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2011 | 430 | 0.090 |
Why?
|
Indoles | 2 | 2019 | 1829 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4713 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3361 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1864 | 0.080 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2018 | 5649 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 319 | 0.080 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4899 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2016 | 2873 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 1 | 2001 | 3387 | 0.080 |
Why?
|
Phosphorylation | 5 | 2014 | 8313 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6544 | 0.080 |
Why?
|
Chromosomes, Human | 1 | 2010 | 442 | 0.080 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2008 | 169 | 0.080 |
Why?
|
Thrombosis | 1 | 2022 | 3052 | 0.080 |
Why?
|
Chlamydophila psittaci | 1 | 2007 | 2 | 0.080 |
Why?
|
Canaries | 1 | 2007 | 6 | 0.080 |
Why?
|
Cell Death | 1 | 2013 | 1672 | 0.080 |
Why?
|
Bird Diseases | 1 | 2007 | 20 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2011 | 2828 | 0.070 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2007 | 71 | 0.070 |
Why?
|
Europe | 3 | 2020 | 3441 | 0.070 |
Why?
|
Chlamydophila Infections | 1 | 2007 | 22 | 0.070 |
Why?
|
Lymphoid Tissue | 1 | 2009 | 445 | 0.070 |
Why?
|
Software | 2 | 2021 | 4419 | 0.070 |
Why?
|
Societies, Medical | 1 | 2020 | 3905 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2011 | 2506 | 0.070 |
Why?
|
Prevalence | 4 | 2019 | 15687 | 0.070 |
Why?
|
Epitopes | 2 | 2011 | 2503 | 0.070 |
Why?
|
Promoter Regions, Genetic | 2 | 2019 | 5785 | 0.070 |
Why?
|
Lymphotoxin-alpha | 2 | 2012 | 94 | 0.070 |
Why?
|
Pyrroles | 1 | 2013 | 1137 | 0.070 |
Why?
|
Bronchial Neoplasms | 1 | 2007 | 110 | 0.070 |
Why?
|
Cell Adhesion | 4 | 2021 | 3094 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2012 | 611 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2019 | 4573 | 0.070 |
Why?
|
Mice, Inbred C57BL | 8 | 2021 | 22023 | 0.070 |
Why?
|
Immunoglobulin Switch Region | 1 | 2006 | 45 | 0.070 |
Why?
|
Cell Line | 5 | 2021 | 15620 | 0.070 |
Why?
|
Chromosomes, Human, Pair 18 | 2 | 2016 | 246 | 0.070 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 2016 | 286 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2015 | 2566 | 0.070 |
Why?
|
Jurkat Cells | 1 | 2008 | 736 | 0.070 |
Why?
|
Alternative Splicing | 2 | 2024 | 1091 | 0.070 |
Why?
|
Palliative Care | 1 | 2021 | 3607 | 0.070 |
Why?
|
Fatigue | 3 | 2019 | 1544 | 0.070 |
Why?
|
Transplantation, Heterologous | 2 | 2016 | 2379 | 0.070 |
Why?
|
NFATC Transcription Factors | 1 | 2008 | 381 | 0.060 |
Why?
|
Tumor Escape | 2 | 2021 | 370 | 0.060 |
Why?
|
Immunity, Innate | 2 | 2020 | 3047 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10551 | 0.060 |
Why?
|
Transcription Factors | 3 | 2024 | 12103 | 0.060 |
Why?
|
Eye Neoplasms | 1 | 2007 | 306 | 0.060 |
Why?
|
Lacrimal Apparatus | 1 | 2007 | 223 | 0.060 |
Why?
|
B-Lymphocyte Subsets | 2 | 2006 | 241 | 0.060 |
Why?
|
Nanoparticles | 1 | 2017 | 1943 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2018 | 4048 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2016 | 15789 | 0.060 |
Why?
|
Mediterranean Region | 1 | 2004 | 47 | 0.060 |
Why?
|
Retreatment | 2 | 2018 | 600 | 0.060 |
Why?
|
Incidence | 4 | 2024 | 21392 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2893 | 0.060 |
Why?
|
Databases, Factual | 2 | 2024 | 8035 | 0.060 |
Why?
|
Genes, bcl-1 | 1 | 2003 | 11 | 0.060 |
Why?
|
Dendritic Cells, Follicular | 2 | 2002 | 50 | 0.060 |
Why?
|
Models, Genetic | 1 | 2014 | 3442 | 0.060 |
Why?
|
Research Personnel | 1 | 2009 | 582 | 0.060 |
Why?
|
Oligodeoxyribonucleotides | 2 | 2017 | 778 | 0.060 |
Why?
|
Pedigree | 2 | 2008 | 4578 | 0.060 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 895 | 0.060 |
Why?
|
Up-Regulation | 3 | 2022 | 4122 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2016 | 5125 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2299 | 0.060 |
Why?
|
Drug Interactions | 2 | 2018 | 1428 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2006 | 2536 | 0.050 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2003 | 121 | 0.050 |
Why?
|
Chemokine CCL20 | 1 | 2003 | 63 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2019 | 3775 | 0.050 |
Why?
|
Receptors, CCR6 | 1 | 2003 | 73 | 0.050 |
Why?
|
Focal Adhesion Kinase 2 | 1 | 2023 | 87 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2019 | 12427 | 0.050 |
Why?
|
Stimulation, Chemical | 1 | 2002 | 306 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2004 | 345 | 0.050 |
Why?
|
Receptors, CXCR5 | 1 | 2002 | 88 | 0.050 |
Why?
|
Hepacivirus | 1 | 2010 | 1334 | 0.050 |
Why?
|
Switzerland | 1 | 2023 | 323 | 0.050 |
Why?
|
Lymphocyte Subsets | 1 | 2003 | 310 | 0.050 |
Why?
|
Neoplastic Stem Cells | 2 | 2002 | 1347 | 0.050 |
Why?
|
Semaphorins | 1 | 2002 | 97 | 0.050 |
Why?
|
Young Adult | 6 | 2024 | 58741 | 0.050 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2022 | 85 | 0.050 |
Why?
|
Receptors, CCR4 | 1 | 2002 | 77 | 0.050 |
Why?
|
Lymphocyte Transfusion | 1 | 2003 | 232 | 0.050 |
Why?
|
Lymph Nodes | 3 | 2016 | 3486 | 0.050 |
Why?
|
Death, Sudden | 1 | 2024 | 302 | 0.050 |
Why?
|
Models, Immunological | 1 | 2004 | 513 | 0.050 |
Why?
|
Receptors, Cytokine | 1 | 2002 | 258 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2013 | 4541 | 0.050 |
Why?
|
Time Factors | 6 | 2020 | 40165 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2020 | 4357 | 0.050 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2024 | 376 | 0.050 |
Why?
|
Receptors, Immunologic | 1 | 2007 | 1411 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2012 | 2981 | 0.050 |
Why?
|
Interleukin-12 | 1 | 2003 | 584 | 0.050 |
Why?
|
Chemotactic Factors | 1 | 2001 | 196 | 0.050 |
Why?
|
Nod2 Signaling Adaptor Protein | 2 | 2012 | 87 | 0.050 |
Why?
|
Chemokine CCL2 | 1 | 2003 | 605 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 345 | 0.040 |
Why?
|
Glycosylation | 1 | 2023 | 1096 | 0.040 |
Why?
|
Virus Activation | 1 | 2022 | 319 | 0.040 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2003 | 632 | 0.040 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 43 | 0.040 |
Why?
|
Antigens, CD19 | 3 | 2011 | 424 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2021 | 277 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2021 | 4264 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2448 | 0.040 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 1998 | 18 | 0.040 |
Why?
|
Aldehyde Oxidase | 1 | 2018 | 4 | 0.040 |
Why?
|
Models, Molecular | 2 | 2021 | 5434 | 0.040 |
Why?
|
Cross-Linking Reagents | 1 | 2002 | 685 | 0.040 |
Why?
|
Smith-Magenis Syndrome | 1 | 2018 | 19 | 0.040 |
Why?
|
Metabolic Networks and Pathways | 1 | 2023 | 789 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2002 | 1130 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2022 | 522 | 0.040 |
Why?
|
Embryonal Carcinoma Stem Cells | 1 | 1998 | 20 | 0.040 |
Why?
|
Carrier Proteins | 2 | 2004 | 4938 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2018 | 115 | 0.040 |
Why?
|
Advisory Committees | 1 | 2022 | 788 | 0.040 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2004 | 1355 | 0.040 |
Why?
|
Amino Acid Substitution | 2 | 2015 | 1737 | 0.040 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2018 | 96 | 0.040 |
Why?
|
Aptamers, Nucleotide | 1 | 2019 | 172 | 0.040 |
Why?
|
bcl-Associated Death Protein | 1 | 1998 | 102 | 0.040 |
Why?
|
Vesicular stomatitis Indiana virus | 1 | 2017 | 92 | 0.040 |
Why?
|
Gene Regulatory Networks | 2 | 2019 | 1741 | 0.040 |
Why?
|
Immunologic Memory | 1 | 2004 | 1354 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2019 | 369 | 0.040 |
Why?
|
Common Variable Immunodeficiency | 1 | 1998 | 102 | 0.040 |
Why?
|
Indazoles | 1 | 2019 | 302 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3202 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11345 | 0.040 |
Why?
|
Histones | 2 | 2019 | 2583 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2010 | 2299 | 0.040 |
Why?
|
Anticoagulants | 3 | 2022 | 4897 | 0.040 |
Why?
|
Creatinine | 1 | 2022 | 1903 | 0.030 |
Why?
|
Patient Preference | 1 | 2024 | 922 | 0.030 |
Why?
|
Chemokine CCL3 | 1 | 2016 | 84 | 0.030 |
Why?
|
Chemokine CCL4 | 1 | 2016 | 126 | 0.030 |
Why?
|
Immunoglobulin Joining Region | 1 | 2016 | 37 | 0.030 |
Why?
|
Chick Embryo | 1 | 1998 | 981 | 0.030 |
Why?
|
Databases, Protein | 1 | 2018 | 388 | 0.030 |
Why?
|
Antigens, CD1d | 1 | 2017 | 217 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 547 | 0.030 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1547 | 0.030 |
Why?
|
Polymorphism, Genetic | 2 | 2017 | 4291 | 0.030 |
Why?
|
World Health Organization | 1 | 2022 | 1312 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2021 | 22053 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2021 | 1982 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2018 | 524 | 0.030 |
Why?
|
Automation | 1 | 2018 | 580 | 0.030 |
Why?
|
bcl-X Protein | 1 | 1998 | 413 | 0.030 |
Why?
|
Clodronic Acid | 1 | 2016 | 59 | 0.030 |
Why?
|
Focus Groups | 1 | 2021 | 1378 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 191 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2017 | 401 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2024 | 1572 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2001 | 1254 | 0.030 |
Why?
|
Dimerization | 1 | 2017 | 891 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 861 | 0.030 |
Why?
|
Hydrogels | 1 | 2021 | 723 | 0.030 |
Why?
|
Adolescent | 5 | 2014 | 87810 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
Dendritic Cells | 2 | 2004 | 2725 | 0.030 |
Why?
|
Actins | 2 | 2014 | 2049 | 0.030 |
Why?
|
Mice, Inbred NZB | 1 | 2014 | 57 | 0.030 |
Why?
|
Receptor, Notch2 | 1 | 2015 | 87 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2012 | 2698 | 0.030 |
Why?
|
Drug Eruptions | 1 | 2018 | 335 | 0.030 |
Why?
|
Phagocytosis | 1 | 2020 | 1535 | 0.030 |
Why?
|
Point Mutation | 1 | 2020 | 1594 | 0.030 |
Why?
|
Safety | 1 | 2019 | 1148 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2010 | 1722 | 0.030 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2017 | 415 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2017 | 11071 | 0.030 |
Why?
|
Tissue Scaffolds | 1 | 2021 | 928 | 0.030 |
Why?
|
DNA Primers | 1 | 1999 | 2819 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2024 | 2255 | 0.030 |
Why?
|
DNA Replication | 1 | 2021 | 1412 | 0.030 |
Why?
|
Aminoquinolines | 1 | 2014 | 108 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 792 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4319 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20080 | 0.030 |
Why?
|
Chromosomes, Mammalian | 1 | 2014 | 146 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2061 | 0.030 |
Why?
|
Ligands | 2 | 2012 | 3276 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2010 | 4878 | 0.030 |
Why?
|
Caspase 8 | 1 | 2014 | 189 | 0.030 |
Why?
|
Immunogenetic Phenomena | 1 | 2013 | 23 | 0.030 |
Why?
|
Arthralgia | 1 | 2018 | 461 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22072 | 0.030 |
Why?
|
Immunoglobulin gamma-Chains | 1 | 2013 | 33 | 0.030 |
Why?
|
Methylation | 1 | 2016 | 1082 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54303 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2015 | 877 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2015 | 388 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2015 | 929 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2002 | 2825 | 0.030 |
Why?
|
Mass Screening | 1 | 2009 | 5423 | 0.030 |
Why?
|
Exanthema | 1 | 2018 | 504 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1895 | 0.030 |
Why?
|
Leukemic Infiltration | 1 | 2012 | 47 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 680 | 0.030 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 508 | 0.030 |
Why?
|
Transfection | 2 | 2015 | 5781 | 0.030 |
Why?
|
Acute Disease | 1 | 2003 | 7269 | 0.030 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2015 | 503 | 0.020 |
Why?
|
Liposomes | 1 | 2016 | 777 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2014 | 1385 | 0.020 |
Why?
|
Pilot Projects | 2 | 2018 | 8555 | 0.020 |
Why?
|
Receptor, Notch1 | 1 | 2014 | 495 | 0.020 |
Why?
|
Health Expenditures | 1 | 2024 | 2362 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4433 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 724 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 551 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 444 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2022 | 2380 | 0.020 |
Why?
|
Cytoplasm | 1 | 2015 | 1516 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2014 | 2176 | 0.020 |
Why?
|
Cell Separation | 1 | 2015 | 1720 | 0.020 |
Why?
|
Telomere | 1 | 2016 | 933 | 0.020 |
Why?
|
Colitis | 1 | 2018 | 1229 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2002 | 4407 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1511 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1997 | 1378 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3061 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 2016 | 1588 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 687 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3442 | 0.020 |
Why?
|
Autophagy | 1 | 2017 | 1337 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5725 | 0.020 |
Why?
|
Luminescent Proteins | 1 | 2012 | 835 | 0.020 |
Why?
|
Cell Shape | 1 | 2010 | 372 | 0.020 |
Why?
|
Nod1 Signaling Adaptor Protein | 1 | 2008 | 13 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2012 | 747 | 0.020 |
Why?
|
RNA | 1 | 2019 | 2722 | 0.020 |
Why?
|
Genetic Markers | 1 | 2015 | 2608 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2648 | 0.020 |
Why?
|
Lipopeptides | 1 | 2008 | 72 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2004 | 3602 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 3726 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2015 | 1738 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2014 | 1039 | 0.020 |
Why?
|
Binding Sites, Antibody | 1 | 2008 | 337 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 2025 | 0.020 |
Why?
|
United States | 3 | 2021 | 72461 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2016 | 4810 | 0.020 |
Why?
|
Headache | 1 | 2015 | 1249 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4417 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6771 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 4035 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2131 | 0.020 |
Why?
|
Ultrasonography | 1 | 2020 | 5961 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9631 | 0.020 |
Why?
|
Antibody Formation | 1 | 2012 | 1400 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 1745 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2011 | 1351 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 2 | 2011 | 3735 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8469 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2004 | 1652 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3602 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2010 | 1900 | 0.020 |
Why?
|
Cytokines | 3 | 2011 | 7343 | 0.020 |
Why?
|
Peptidoglycan | 1 | 2008 | 250 | 0.020 |
Why?
|
Sequence Homology | 1 | 2006 | 195 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 2006 | 346 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 11903 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2015 | 2907 | 0.020 |
Why?
|
Medication Adherence | 1 | 2018 | 2165 | 0.020 |
Why?
|
Greece | 1 | 2006 | 336 | 0.020 |
Why?
|
Rheumatoid Factor | 1 | 2006 | 185 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2471 | 0.020 |
Why?
|
Doxycycline | 1 | 2007 | 341 | 0.020 |
Why?
|
Oligonucleotides | 1 | 2008 | 588 | 0.020 |
Why?
|
Thiazoles | 1 | 2013 | 1511 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2005 | 225 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 211 | 0.020 |
Why?
|
Environmental Health | 1 | 2007 | 284 | 0.020 |
Why?
|
France | 1 | 2006 | 511 | 0.020 |
Why?
|
Spain | 1 | 2006 | 488 | 0.020 |
Why?
|
DNA | 1 | 2019 | 7233 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 3201 | 0.010 |
Why?
|
Child, Preschool | 4 | 2016 | 42063 | 0.010 |
Why?
|
Mice, Nude | 1 | 2010 | 3607 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2006 | 1060 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2011 | 1889 | 0.010 |
Why?
|
CpG Islands | 1 | 2008 | 1221 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2005 | 630 | 0.010 |
Why?
|
Cell Migration Inhibition | 1 | 2003 | 97 | 0.010 |
Why?
|
Gene Silencing | 1 | 2010 | 1513 | 0.010 |
Why?
|
Chemokine CXCL9 | 1 | 2003 | 135 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8552 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10827 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14495 | 0.010 |
Why?
|
Graft vs Tumor Effect | 1 | 2003 | 68 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 2004 | 468 | 0.010 |
Why?
|
Antigens, Bacterial | 1 | 2008 | 1155 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2018 | 3455 | 0.010 |
Why?
|
Interferon-gamma | 2 | 2004 | 3157 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2014 | 2093 | 0.010 |
Why?
|
Basement Membrane | 1 | 2003 | 348 | 0.010 |
Why?
|
Chemokine CXCL10 | 1 | 2003 | 316 | 0.010 |
Why?
|
STAT1 Transcription Factor | 1 | 2003 | 333 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6238 | 0.010 |
Why?
|
Palatine Tonsil | 1 | 2002 | 193 | 0.010 |
Why?
|
Cell Cycle | 1 | 2010 | 2934 | 0.010 |
Why?
|
Amino Acids | 1 | 2007 | 1714 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12159 | 0.010 |
Why?
|
Proteomics | 1 | 2014 | 3817 | 0.010 |
Why?
|
Chromatin | 1 | 2012 | 2938 | 0.010 |
Why?
|
International Cooperation | 1 | 2006 | 1433 | 0.010 |
Why?
|
Blood Transfusion, Autologous | 1 | 1999 | 132 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2002 | 1991 | 0.010 |
Why?
|
Binding Sites | 1 | 2007 | 6048 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2012 | 3826 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 13981 | 0.010 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2000 | 691 | 0.010 |
Why?
|
Hemolysis | 1 | 1999 | 423 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2005 | 1974 | 0.010 |
Why?
|
Inflammation | 1 | 2017 | 10756 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2006 | 2203 | 0.010 |
Why?
|
Endothelium | 1 | 1999 | 764 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 237 | 0.010 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 1997 | 516 | 0.010 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2000 | 1126 | 0.010 |
Why?
|
Child | 3 | 2016 | 79806 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12960 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2003 | 1726 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24123 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4463 | 0.010 |
Why?
|
CHO Cells | 1 | 1997 | 1389 | 0.010 |
Why?
|
Trans-Activators | 1 | 2003 | 2860 | 0.010 |
Why?
|
Cricetinae | 1 | 1997 | 2427 | 0.010 |
Why?
|
Liver | 1 | 2007 | 7509 | 0.010 |
Why?
|
Infant | 2 | 2005 | 36060 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2003 | 3025 | 0.010 |
Why?
|
Reference Values | 1 | 1997 | 4925 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 7408 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1999 | 26181 | 0.000 |
Why?
|